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Abstract
Background: The objective of these two GCP multicentre European clinical field studies was to evaluate the long-
term efficacy and safety of a new imidacloprid/flumethrin collar (Seresto
®, Bayer AnimalHealth, Investigational
Veterinary Product(IVP)) in dogs and cats naturally infested with fleas and/or ticks in comparison to a dimpylat
collar ("Ungezieferband fuer Hunde/fuer Katzen”, Beaphar, Control Product (CP)).
Methods: 232 (IVP) and 81 (CP) cats and 271(IVP) and 129 (CP) dogs were treated with either product according to
label claims and formed the safety population. Flea and tick counts were conducted in monthly intervals for up to
8 months in the efficacy subpopulation consisting of 118 (IVP) + 47 (CP) cats and 197 (IVP) + 94 (CP) dogs. Efficacy
was calculated as reduction of infestation rate within the same treatment group and statistically compared
between the two treatment groups.
Results: Preventive efficacy against fleas in cats/dogs varied in the IVP group between 97.4%/94.1% and 100%/
100% (overall mean: 98.3%/96.7%) throughout the 8 month period and in the CP group between 57.1%/28.2% and
96.1%/67.8% (overall mean: 79.3%/57.9%). Preventive efficacy against ticks in cats/dogs varied in the IVP group
between 94.0%/91.2% and 100%/100% (overall mean: 98.4%/94.7%) throughout the 8 month period and in the CP
group between 90.7%/79.9% and 100%/88.0% (overall mean: 96.9%/85.6%). The IVP group was statistically non-
inferior to the CP group, and on various assessment days, statistical superiority was proven for flea and tick count
reduction in dogs and cats. Both treatments proved to be safe in dogs and cats with mainly minor local
observations at the application site. There was moreover, no incidence of any mechanical problem with the collar
in dogs and cats during the entire study period.
Conclusions: The imidacloprid/flumethrin collar proved to reduce tick counts by at least 90% and flea counts by at
least 95% for a period of at least 7-8 months in cats and dogs under field conditions. Therefore, it can be used as
sustainable long-term preventative, covering the whole flea and tick season.
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Fleas and ticks are common ectoparasites in dogs and cats
and are present in many areas of the world, in differing
intensity depending on the climatic conditions. Fleas are
present in all areas of Europe, with Ctenocephalides felis
being the most frequent flea species on our companion
animals followed by Ctenocephalides canis.T h em a i n
European tick species are Rhipicephalus sanguineus (dog);
Ixodes ricinus (cat and dog), Dermacentor reticulatus (dog)
and Rhipicephalus turanicus (cat). The latter species is not
very well recognized but recently acknowledged to be the
species present on cats instead of the nearly identical but
very dog specific R. sanguineus [1]. Fleas tend to occur
from spring to winter and are capable of acting as vectors
for several diseases, e.g. bartonellosis and tapeworms, and
can cause flea allergic dermatitis (FAD). Ticks peak from
early spring to late autumn and are important vectors for
several diseases, e.g. borreliosis, anaplasmosis, ehrlichiosis
and babesiosis. In humans they can transmit tick encepha-
litis, borreliosis and anaplasmosis. Both fleas and ticks play
an important role as vectors [2]. Therefore, effective mea-
sures against these parasites are important in preventing
feline, canine and human disease [3].
While there are many authorized products containing
different active ingredients for the prevention of fleas,
there are only a few products available against ticks. Pro-
ducts containing fipronil are almost the only option for
tick treatment of cats and dogs as the other common acar-
icides, permethrin and amitraz, are indicated for dogs only
[4,5] and are contraindicated for use in cats due to serious
safety concerns. Flumethrin, the acaricidal active compo-
nent in Kiltix
® collars (propoxur 10%/flumethrin 2.25%),
i sah i g h l yp o t e n ta c a r i c i d ek n o w nt ob es a f ei nv a r i o u s
animal species including cattle, sheep and dogs but also
cats: the Kiltix
® collar was, up to-date the only broadly
marketed pyrethroid containing formulation suitable for
cats.
Formulations of these active ingredients are generally
designed for topical application with the most common
versions being collars and low volume fluids (spot ons):
Collars have been used frequently for the treatment and
prevention of flea and tick infestations in dogs and cats in
the past decades in Europe and abroad [6,7]. However,
with the launch of spot-on topical formulations and con-
cerns about the perceived potential risk for free roaming
cats to be trapped by any salient piece of wood or other
rigid material, collars have been less involved in the grow-
ing market for flea and tick control.
Seresto
® (Bayer Animal Health), a new collar for dogs
and cats, provides long term broad spectrum parasiticidal
activity by combining the insecticidal properties of imida-
cloprid with the acaricidal properties of flumethrin. The
collar matrix system ensures that both active ingredients
are slowly and continuously released from the collar
towards the animal thereby avoiding peak concentrations
and ensuring that acaricidal/insecticidal concentrations
of both active ingredients are present in the cat’s or dog’s
hair coat during the entire efficacy period. The active
ingredients spread from the site of direct contact over
the entire skin surface of the treated animal [8].
Following application of the collar, both active ingredi-
ents remain on the outer surface of the animal’s skin and
hair coat, enabling them to come into contact with the tar-
get parasites and display their efficacy. The neonicotinoid
imidacloprid interacts with the nicotinic acetylcholine
receptors (nAChRs) on the post-synaptic membrane [9],
while flumethrin, as an a-cyano-(type II)-pyrethroid, exhi-
bits excitatory efficacy by blocking the voltage gated axo-
nic sodium channels [9]. As recently described in
laboratory studies [9], imidacloprid and flumethrin have
synergistic efficacy on insects, in particular fleas. Both
active ingredients are well known on the ectoparasiticide
market: imidacloprid has been the insecticidal active ingre-
dient in products such as Advantage
®, Advantix
® and
Advocate
® since 1996 while flumethrin has been regis-
tered since 1986 for animal use and has already been used
extensively in livestock animals (esp. cattle). It has also
been used for more than a decade in the EU as an active
ingredient in companion animal products (dogs and in
parts of the EU also cats): Kiltix
® collar [6].
As usual for clinical field studies, a full set of laboratory
efficacy and safety studies was a prerequisite for conduct-
ing the herein described studies. According to a set of pre-
ceding laboratory in-vivo studies the collar provides long
term (8 month) prevention for cats and dogs against ticks
(cats: I. ricinus, R. turanicus (= the Rhipicephalus species
on cats,[ 1 ] ) dogs: I. ricinus, I. scapularis, R. sanguineus,
D. reticulatus) and fleas (C. felis,) [10,11]. The collar
proved also to be effective against the tick species
Amblyomma americanum (USA) and Dermacentor varia-
bilis (USA) [10,11]. The collar’s safety has been shown in
longterm, overdosage studies following the guideline on
target animal safety (VICH GL43) as well as US EPA
requirements at up to 5 times the target dose in both cats
a n dd o g s ,1 0w e e ko l dk i t t e n sa n d7w e e ko l dp u p p i e s
[12]. Additionally, to this standard study set, a specific pro-
duct safety concern for cats was addressed before study
start: their particular sensitivity towards pyrethroids [13].
This sensitivity is generally explained by a reduced enzyme
pattern for hydrolysis of pyrethroid-esters in cats, and by
toxic metabolites developing during the pyrethroid degra-
dation process combined with the reduced glucuronida-
tion and therefore excretion capacity of the feline liver
[14-16]. Opposite to e.g. permethrin and deltamethrin, the
metabolism of flumethrin is simple without the need for
glucuronidation. Flumethrin itself or its main metabolite
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feces [17]. Moreover, flumethrin acid is pharmacologically
inactive [18]. The decreased feline glucuronidation rate is
therefore toxicologically irrelevant [17]. Accordingly the
NOAEL (No Observed Adverse Effect Level) for flume-
thrin is identical for dogs and cats [19]. The already rather
low flumethrin toxicity in cats is complemented in this
new product by two other aspects: only a very low hair
coat concentration of this highly effective acaricide is
necessary for high efficacy against ticks, and this low
amount is released steadily from the collar without peak
concentrations [9]. These three aspects together form the
basis for the collar to be a useful application form for an
effective and safe cat acaricide.
This results in a special benefit of the imidacloprid 10%/
flumethrin 4.5% collar when tick and flea treatment is
necessary in mixed cat and dog households. As the cat
and dog products are identical, dogs living closely together
with cats can be protected against ectoparasites without
safety concerns about cats potentially ingesting critical
amounts of active ingredient through mutual grooming.
Besides the classical target animal safety evaluation, the
particular pharmaceutical application via a collar bears
another safety relevant aspect for cats which was taken
into account and tested before the collar was used in the
discussed field study: in contrast to dogs, which usually
wear constantly leather or chain collars, cats are less
often equipped with these accessories by their owners.
The reason for this is the different behaviour of this spe-
cies; free roaming cats displaying the full range of their
hunting instinct are known to roam through wood, scrub
or other wayless terrain and to pass through particularly
narrow apertures when hunting their prey. Cat owners
often fear that cats may be captured or strangulated by a
collar, which may get caught on any salient piece of
wood or other rigid material, and so cats are perceived to
be more at risk wearing a collar. The new collar has an
integral safety-closure ratchet mechanism that is con-
structed to yield at approximately 50 Newton (~5 kg)
traction [Jiritschka W, Imidacloprid/Flumethrin - collar:
Determination of force needed to re-open the collar
using the integral closing system, unpublished], and
a l l o w st h ec o l l a rt ob ew i d e n e db yt h ed i s t a n c et ot h e
next rib. Widening by two or three rib spaces will usually
easily allow a cat to escape from the collar in the unlikely
case that it gets trapped. 50 Newton is the force a 2 kg
cat needs to jump to a height of just 40 cm. This is easily
brought to bear by even a small cat, which seriously
wants to escape from somewhere but is strong enough to
keep the collar on the cat’s neck under normal circum-
stances and to prevent the cat from accidentally losing it.
Additionally the collar design prevents the collar from
widening to the extent that can occur in certain elastic
collars, where cats may be endangered by getting the
front leg stuck in the over-widened collar; in this case
severe skin damage may occur as the leg becomes hooked
at the elbow and cannot be retracted by the animal itself.
A second, backup security feature for cats is represented
by the “pre-determined breaking point” of the cat collar.
In contrast to the approximate 140 Newton (~14 kg) trac-
tion necessary to break the cat collar itself, this pre-deter-
mined area breaks at approximately 80 Newton (~8 kg)
[Jiritschka W, Imidacloprid/Flumethrin - collar: Determi-
nation of force needed to disrupt the collar, unpublished].
So even in cases where the safety-closure mechanism is
blocked by any unfortunate accident, the animal has an
increased chance to escape by breaking the collar.
The extended safety profile described above and initial
efficacy data of the new collar in both cats and dogs was a
prerequisite to apply for permission to use it in pets natu-
rally infested with fleas and ticks under field conditions.
The objective of the present therapeutic confirmatory,
controlled, randomised, blocked, multi-centre and multi-
regional field study was accordingly to confirm the long-
term efficacy and safety of the combination of “imidaclo-
prid 10%/flumethrin 4.5%” administered by collar for the
treatment of natural infestations of fleas and/or ticks in
cats and dogs, presenting as patients in European veterin-
ary practices and based on statistical non-inferiority as
compared with a licensed collar product for cats and dogs.
Statistical non-inferiority of the imidacloprid/flumethrin
collar (IVP) compared to the control product (CP) was
shown if the lower limit of the two-sided 97.5% confidence
interval of the difference between IVP and CP was greater
than -15%.
Methods
Investigational Veterinary Product (IVP) and Control
Product (CP)
The new imidacloprid 10%/flumethrin 4.5% collar under
investigation (IVP) is a grey, odourless polymer matrix col-
lar containing 10% (w/w) imidacloprid and 4.5% (w/w) flu-
methrin. The collar is designed to be fixed around the
neck of cats and dogs and comes in two different sizes for
dogs and one size for cats. The length of the collar can be
adapted to the size of the animal with a ratchet closure
mechanism and by cutting the overlapping end to the
required length. Administration route, schedule, dose and
dosage form of the IVP and the CP “Beaphar Ungeziefer-
band fuer Hunde/fuer Katzen”, a collar containing Dimpy-
lat and authorised for dogs and cats for the control of flea
and tick infestations in several EU countries including
Germany are shown in Table 1.
General design
Two multicentre, multiregional positive controlled clinical
field studies, one in cats and one in dogs, were conducted
with the IVP imidacloprid 10%/flumethrin 4.5% collar,
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in cats and dogs for 8 months and compared to a positive
control product (CP) “Beaphar Ungezieferband fuer
Hunde/fuer Katzen”. These clinical field studies were car-
ried out in 33 practices/clinics, and patients were actively
enrolled from different geographical areas in Europe
(France, Germany, Hungary and Portugal).
The IVP collar treatment was given once during the
study except in cases when the animals lost the collar
and it had to be replaced, whereas the CP with its shorter
label efficacy of 5 months was replaced after 5 months of
wear (approx. day 140). Non-inferiority of the IVP in
comparison to the CP was tested comparing baseline to
post-treatment parasite counts as observed on day 2 and
then every 28 days post treatment.
Procedure
After the informed owner consent had been obtained,
animals were enrolled based on predefined in- and exclu-
sion criteria. Depending on the identified parasites they
were allocated either to the flea or to the tick subgroup
of the total efficacy population (per-protocol popula-
tion, PP). Within the subgroups, they were randomly
allocated to treatment in a ratio of 2:1 to either the IVP
or the CP group. For flea infestations (an animal with at
least 5 viable fleas), the primary animal of a multipet
household was the experimental unit and formed part of
the efficacy population (per-protocol population). Other
animals of this household were treated with either the
same product as the primary animal (supplementary ani-
mals) or, if contraindicated, with a product of choice of
the investigator (additional animals). For tick infestations,
each individual animal hosting at least 3 viable and
attached ticks was enrolled and the individual animal was
the experimental unit. Primary and supplementary ani-
m a l so ft h ef l e ap a r to ft h es t u d yt o g e t h e rw i t ha l lt i c k
patients formed the safety population (intention-to-
treat population, ITT).
Day 0 was defined individually as the day an animal was
found suitable for enrolment in the study and was treated
with either treatment. Study completion was the day the
animal completed the study, normally day 238, unless it
was previously withdrawn from the study. Animals under-
went parasitological and clinical assessments on day 0 and
thereafter in monthly intervals (every 4 weeks) until day
238. These intervals were treated in the statistical evalua-
tion as “post baseline periods”. All visits (except visit on
day 2: ± 1 day) were performed within a range of ± 2 days
of the target day.
Parasitological examinations
Tick and flea counts were performed by the examining
veterinarian as complete body counts according to a
defined procedure, using manual palpation for ticks and
additional fine-toothed flea combs for fleas. Counting
was terminated at 10 minutes after the last identification
of a flea or tick. Parasites were collected, fixed in ethanol
and stored for species determination at a later stage. The
species and developmental stage of the collected ticks
from dogs and cats were identified by the Department of
Comparative Tropical Veterinary Medicine, LMU
Munich, Germany. The identification of collected fleas
was performed by Bayer Animal Health GmbH, Mon-
heim, Germany. Both institutes conducted the identifica-
tion according to approved internal Standard Operation
Procedures, using a number of morphological keys, either
published (such as e.g. the Catalogue of the Rothschild
Collection of Fleas [20]) or unpublished, internal expert’s
material (such as extensive descriptions and photos).
Clinical and safety observations
Primary animals were observed on day 2 and monthly
thereafter for clinical signs, dermatological changes at the
application site and adverse events, which were then cate-
gorized into suspected adverse drug reactions (SADR) and
events unrelated to treatment. Supplementary animals
were observed at least once at the end of the study by the
study veterinarians for changes at the application site and
for adverse events. Additionally, all animals were under
daily supervision of their owners who were obliged to
report any adverse events, especially signs of collar side
effects, to their veterinarian as soon as they appeared.
Data handling and analysis
Data from all study animals were entered into StudyBase
®,
an electronic data capture solution specifically designed
Table 1 Products used and treatment regimen according to the product label requirements
ivp or CP Route Schedule Dose (per animal) Dosage Forms Used for
Imidacloprid/
Flumethrin collar
(Seresto
®)
Topical as
a collar
Once on day 0 One collar, length adapted to size of animal
based on neck size: 100 mg Imidacloprid
and 45 mg Flumethrin/g collar
Small collar(≥ 1.0 kg to ≤ 8.0
kg bodyweight (b.w).) Large
collar (> 8.0 kg b.w.)
Dogs/cats Dogs
Dimpylat collar
(Ungezieferband
fuer Hunde
®)
Topical as
a collar
Once on day 0
and day 140 ± 2
One collar, length adapted to size of animal
based on neck size: Equal to 3.6 g
Dimpylat/24 g collar
One collar size Dogs
Dimpylat collar
(Ungezieferband
fuer Katzen
®)
Topical as
a collar
Once on day 0
and day 140 ± 2
One collar, length adapted to size of animal
based on neck size: Equal to 2.1 g
Dimpylat/14 g collar
One collar size Cats
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validated prior to use. After verification of the data, they
were downloaded to SAS
® for analysis (SAS Institute Inc.,
Cary, NC, USA, version 9.2).
Statistical analysis
The primary (overall) efficacy of the investigational veter-
inary product was defined as the average viable tick or flea
count reduction compared to the day 0-baseline over the
entire treatment period (8 months) and was compared to
the control product using a test of non-inferiority cor-
rected to baseline.
The percentage of flea and tick count reduction com-
pared to baseline was calculated for each monthly evalua-
tion period. Mean percentage reduction over all post-
baseline periods was compared between treatment
groups using a non-inferiority margin of 15%. Non-infer-
iority of IVP compared to CP was shown if the lower
limit of the two-sided 97.5% confidence interval of the
difference between IVP and CP was greater than -15%.
This corresponds to the following test hypotheses:
H0 :P R IVP ≤ PRCP − 15%
HA :P R IVP > PRCP − 15%
with PRIVP resp PRCP being the least square means of
percentage reduction over all post-baseline periods for
the IVP compared to the CP calculated in an analysis of
variance with repeated measurements adjusted for base-
line (main effect of treatment over all post-baseline
periods).
For calculation of the percentage parasite count reduc-
tion (PR) the following formula was used for each indi-
vidual animal:
count(period1) − count(periodi)
count(period1)
× 1 0 0=P Ra tP e r i o di
for i = 2 to 11 (post-baseline evaluation periods) and
period 1 = baseline.
As a secondary efficacy criterion, tick and flea count
reductions (compared to baseline) were assessed sepa-
rately for each single post-baseline period to evaluate
superiority of the IVP compared to the control group.
Additionally the prevalence of concurrent tick and/or
flea infestations was evaluated for the whole study per-
iod and the percentage of patients showing Flea Allergic
Dermatitis (FAD) was calculated for each observation
day.
Results
The total safety population (intention to treat popula-
tion, ITT) consisted of 400 dogs and 313 cats, of which
271 dogs and 232 cats were treated with the imidacloprid
10%/flumethrin 4.5% collar (IVP) and 129 dogs and 81
cats were treated with the CP (Table 2). The efficacy
population (per protocol population, PP) consisted of
118 (IVP) + 47 (CP) cats and 197 (IVP) + 94 (CP) dogs.
As common in this type of study, the number of control
animals (CP group) was considerably smaller than the
number of animals in the IVP group. The CP animal
number was confirmed to be sufficient by the proof of
statistical comparability of IVP and CP in terms of epide-
miological data (gender, neutered, pure-bred, age, weight,
coat length, husbandry and living place (urban or country
side). All comparisons resulted positively in values
between p > 0.05 up to 1.00, except one single value in
the cat PP flea population (hair coat length; p = 0.048).
The investigational product showed a long and reliable
efficacy against fleas and ticks over the complete 8
months study period, which significantly exceeded the
efficacy of the control product efficacy (except for tick
efficacy in cats where superiority of the IVP was shown
for months 2-4 only). A good tolerability of the IVP was
s h o w nw i t ho n l yaf e w( 9 %i ncats/1.04% in dogs) minor
local tolerance events mostly due to the mechanical influ-
ence of the collar, such as erythema, alopecia, scratching
and cosmetic effects such as hair discoloration.
At enrolment, treatment groups were assessed for any
differences regarding breeds, coat length, husbandry and
tick and flea counts and no relevant differences were
observed between groups. At enrolment (day 0), C. felis
was found to be the most prevalent flea species identified
in cats (96.8%) and dogs (94.0%), while C. canis (0% and
12.0%), A. erinacei (3.2% and 2.4%) and P. irritans (1.6 and
3.6%) were also identified. Tick species identified from
viable ticks at day 0 in cats and dogs respectively were:
D. reticulatus (1.8% and 18.4%), I. hexagonus (7.1% and
11.4%), I. ricinus (89.3% and 64.9%) and Rhipicephalus
spp. (most probably turanicus/sanguineus) (8.9% and
28.1%). Other tick species identified in very low numbers
included Haemaphysalis spp., I. canisuga and Ixodes spp.
(Table 3).
Efficacy
Efficacy of the imidacloprid 10%/flumethrin 4.5% collar in
comparison to the control product is illustrated for cats in
Figures 1 and 2 and for dogs in Figures 3 and 4. All calcu-
lations are based on arithmetic mean data in accordance
with the EU Guideline for the testing and evaluation of the
efficacy of antiparasitic substances for the treatment and
prevention of tick and flea infestation in dogs and cats
(EMEA/CVMP/005/2000- Rev.2).
Overall efficacy against fleas and ticks (primary efficacy
criterion)
Based on the efficacy population (per protocol popula-
tion) the mean percent reduction of flea counts in the
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in the CP group it was 79.3% in cats and 57.9% in dogs for
t h eo v e r a l ls t u d yp e r i o d( T a b l e4 ) .T h em e a np e r c e n t
reduction of tick counts in the IVP group was 98.4% in
cats and 94.7% in dogs whereas in the CP group it was
96.9% in cats and 85.6% in dogs for the overall study
period (Table 4). Non-inferiority (lower 97.5% confidence
interval of least square mean difference greater than -15.0)
was shown for the IVP groups (cats and dogs) compared
to the control groups (cats and dogs). Based on the base-
line counts of all animals treated (intention-to-treat
population), superiority of the imidacloprid 10%/
Table 2 Study design and allocation to treatment of safety population (= Intent to Treat Population, ITT) and efficacy
population (= Per Protocol Population, PP)
Dog study
Group Randomised as Observation days
tick patients flea patients
“Imidacloprid and Flumethrin” (IVP) 139 (114) 132 (83) Day 0
Dimpylat (CP) 63 (52) 66 (42) Day 2 (+1)
Total evaluated 400 (291) Day 28 (± 2)
Day 56 (± 2)
Day 84 (± 2)
Day 112 (± 2)
Day 140 (± 2)
Day 168 (± 2)
Day 196 (± 2)
Day 224 (± 2)
Day 238 (± 2)
Cat Study
Imidacloprid/Flumethrin (IVP) Dimpylat (CP) 159 (62) 73 (56) Day 0
52 (21) 29 (27) Day 2 (+1)
Day 28 (± 2)
Day 56 (± 2)
Day 84 (± 2)
Day 112 (± 2)
Day 140 (± 2)
Day 168 (± 2)
Day 196 (± 2)
Day 224 (± 2)
Day 238 (± 2)
Total cats evaluated 313 (166)
Table 3 Tick and flea species identified on dogs and cats (as percentage of primary IVP animals) and percentage of
patients with mixed flea and tick infestation
Results Dogs Cats
Flea species identified:
(% of primary IVP animals)
Ctenocephalides felis (96.7%) Ctenocephalides felis (91.9%)
Ctenocephalides canis (0.5%) Ctenocephalides canis (11.6%)
Pulex irritans (0.5%) Pulex irritans (2.0%)
Archaeopsylla erinacei (3.3%) Archaeopsylla erinacei (2.0%)
Tick species identified:
(% of IVP animals)
Ixodes ricinus (89.2%) Ixodes ricinus (64.9%)
Ixodes hexagonus (8.8%) Ixodes hexagonus (8.4%)
Rhipicephalus spec. (8.8%) Rhipicephalus sanguineus (28.2%)
Dermacentor reticulatus (2.9%) Dermacentor reticulatus (18.8%)
Patients with mixed flea/tick infestations 3.2% of animals 3.5% of animals
5.3% of households 5.7% of households
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the control product was proven.
Efficacy comparison per study day for ticks and fleas
(secondary efficacy criterion)
Efficacy at day 2 (curative efficacy) Curative efficacy
against fleas and ticks already on the animal at the time-
point of treatment (day 0) is described by the study day 2
flea and tick count reduction. For fleas, it was 92.9% and
71.8% in cats and 86.7% and 66.5% in dogs for the IVP
and CP group, respectively. For ticks, it was 94.8% and
97.7% in cats and 79.9% and 86.6% in dogs for the IVP
and CP group, respectively.
Efficacy at day evaluation time points post day 2 (pre-
ventive efficacy) From day 28 to day 238 the IVP group
reached more than 95% percent flea count reduction
based on both the cat (exception day 28 (94.1%)) and
the dog efficacy population whereas the control group
never reached the threshold of 95% flea count reduction
during the 8 months study duration. The IVP was
superior to the control product at every flea count time
point in dogs and cats and at various tick assessment
time points (Table 4). Superiority of the imidacloprid
10%/flumethrin 4.5% collar was tested using ANOVA
adjusted to baseline at p < 0.05. From day 28 to day 238
Figure 1 Percentage reduction of viable fleas in cats for each
efficacy evaluation period - arithmetic means and 95%
confidence limits (PP population).
Figure 2 Percentage reduction of viable ticks in cats for each
efficacy evaluation period - arithmetic means and 95%
confidence limits (PP population).
Figure 3 Percentage reduction of viable fleas in dogs for each
efficacy evaluation period - arithmetic means and 95%
confidence limits (PP population).
Figure 4 Percentage reduction of viable ticks in dogs for each
efficacy evaluation period - arithmetic means and 95%
confidence limits (PP population).
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Page 7 of 11the IVP group reached more than 90% percent tick
count reduction based on both the cat and the dog effi-
cacy population whereas the control group showed
values above 90% only in cats and did not reach at any
time within the 8 months 90% tick count reduction in
dogs.
The non-parametric Wilcoxon test confirmed the
results of the ANOVA analysis.
Concurrent flea and tick infestations
Concurrent flea and tick infestations were observed in
3.2% and 3.5% of the dogs and cats and in 5.3% and
5.7% of the assessed households (Table 3).
Flea Allergic Dermatitis (FAD)
The influence of IVP and CP treatment on FAD was
evaluated for both treatment groups. In addition, to
evaluate the curative efficacy of the new collar in parti-
cular, and in order not to overestimate its efficacy on
F A D ,t h ei n d i v i d u a lc l i n i c a lc a s er e c o r d so ft h eI V P
group were further investigated to evaluate the influence
of palliative glucocorticoid treatments to the treatment
success:
Cats O nt h ee n r o l m e n td a y( s t u d yd a y0 ) ,1 8( 7 . 8 % )o f
the 231 cats in the IVP-ITT population showed symp-
toms of FAD. By SD 2 this number was reduced to 14
(6.1%) and FAD was completely cured at the SD 28 eva-
luation. Only one new case came up at SD 196. Since no
further investigations were conducted in this animal, the
reason/correct diagnosis cannot be definitively clarified,
especially since the flea counts were zero. In the CP
group, 8 (10%) out of the 80 cats in the ITT population
started the study with FAD already present. FAD cases in
the CP group also declined rapidly within the first 28
days after treatment to between very few to no flea aller-
gic animals.
Description of palliative FAD treatment in the IVP
group Palliative treatment was not prohibited for the
study animals. Only five FAD positive cats were concomi-
tantly treated once with a glucocorticoid against FAD at
SD0 in parallel to the collar application, and only one of
these treatments contained a depot formulation. Of the
18 FAD cases found in the cat population, the 4 short
term and one long term glucocorticoid treated cats repre-
sent 28% of this subgroup and the rest of the cases
resolved without any additional treatment.
Dogs On the inclusion day, 23 (8%) of the 286 dogs in
the ITT population showed symptoms of FAD. By SD 2
this number was reduced to 16 (5.6%), and consequently
decreased to 4 (1.4%) at SD 28. FAD completely vanished
at the SD 56 evaluation, apart from one persistent case,
which remained visible up to SD 168 before a full cure
was achieved. At the very end of the study (SD 238), two
new cases came up. Since no further investigations were
conducted in these animals, the reason/correct diagnosis
cannot be definitively clarified, especially since the flea
counts were zero. In the CP group, 12 (8.8%) out of the
136 dogs in the ITT population started the study with
FAD already present. FAD cases in the CP groups also
declined rapidly within the first 28 days after treatment
to between very few to no flea allergic animals.
Description of palliative FAD treatment in the IVP
group Only one FAD positive dog was concomitantly
treated once with a short term glucocorticoid against
FAD at SD0 in parallel to the collar application, more-
over, one FAD positive dog at study inclusion had a his-
tory of being treated one month before collar application
with a glucocorticoid. Of the 23 FAD cases found in the
dog population, the one short term glucocorticoid treated
animal represents 4.3% of this subgroup whereas the rest
of the cases resolved without any additional treatment.
Safety
The number of adverse events suspected to be treatment
related was evaluated for both treatments and evidence
was compared statistically. In cats, a total of 28 events
were suspected to be related to study medication (Sus-
pected Adverse Drug Reactions (SADRs)), 23 in the IVP
(9.0% of the IVP safety population) and 5 in the control
group (5.6% of the CP safety population). This difference
was not statistically significant (p > 0.4; Fisher’s exact test).
Cat SADRs were generally mild dermal reactions (alopecia,
pruritus, mild contact dermatitis).
In dogs, in the IVP group 3 events (alopecia, hair colora-
tion, dermatitis) and in the CP group 4 events (alopecia,
flea infestation, pruritus, aggressive behaviour towards a
collar wearing animal) were scored as being related to the
study medication. The difference between the two groups
Table 4 Efficacy results based on tick and flea count
reduction as compared to the baseline counts on Day 0
Results Cat study Dog study
Efficacy ** Fleas Ticks Fleas Ticks
Treatment group IVP CP IVP CP IVP CP IVP CP
SD2-4 (96 h) curative 92.9* 71.8 94.8 97.7 86.7* 66.5 79.9 86.6
month 1 99.0* 87.1 94.0 96.3 94.1 48.6 93.4* 85.2
month 2 99.7* 57.1 99.3* 90.7 98.0* 28.2 97.8* 81.4
month 3 100* 90.2 97.9* 90.0 97.4* 48.6 98.8* 81.1
month 4 99.8* 76.9 100* 96.6 99.1* 56.1 98.2* 86.9
month 5 97.4* 68.1 99.4 100 97.5* 51.0 98.8* 83.4
month 6 99.1* 63.9 99.6 96.3 99.6* 60.5 98.5 88.0
month 7 99.8* 87.4 100 100 99.9* 67.3 97.9 88.0
month 8 99.3* 87.8 99.6 100 100 69.8 91.2* 79.9
m 8 (+14 d) (SD238) 99.8* 96.1 100 100 100* 67.8 99.8 90.7
Overall 98.3* 79.3 98.4* 96.9 96.7* 57.9 94.7* 85.6
*Efficacy of IVP is statistically superior to CP (p < 0.05; ANOVA adjusted for
baseline or non-parametric Wilcoxon test), as evaluated from PP
population**Efficacy calculations (PP population) were based on arithmetic
means
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test)
Discussion
General
The two studies reported here were conducted accord-
ing to VICH GCP, which assured the accurateness,
integrity and correctness of the observations. The stu-
dies were controlled by a positive control group, animals
were randomised to treatment groups and the laboratory
scientists conducting the identification of parasites were
blinded with respect to treatment group. Although the
investigators counting the fleas and/or ticks could not
be blinded due to the nature of the treatments, the pos-
sible influence of bias is nevertheless limited: parasite
counts are an objective measure and a standard proce-
dure was followed to guarantee accurate and compar-
able parasite counts at all study sites throughout the
study period.
Efficacy
The evaluated flea counts confirm the results described
for imidacloprid and imidacloprid combinations by var-
ious authors [21-24]. However, the duration of efficacy
against fleas of the previously licensed spot-on formula-
tions of imidacloprid is about one month for Advan-
tage
®, Advocate
® and Advantix
® (Bayer Animal Health)
respectively, while the collar exhibits a long-term effi-
cacy for 8 months. The same applies to ticks, where the
efficacy duration of spot on products is usually limited
to 3-4 weeks, depending on tick species (Advantix
®,
Frontline Combo
®) or, for cats is even shorter (2 weeks;
Frontline Combo
® cat). The therapeutic need in cats is
quite evident as, apart from this product, the availability
of acaricides for this species is highly limited.
Efficacy for a period of eight months had been proven
as prerequisite for the field study in fleas and numerous
tick species in laboratory studies reported by Stanneck
et al. [10,11]. The fast onset of protective insecticidal,
acaricidal and repellent efficacy (immediately in fleas, as
to 24 h counts; within 48 hours in ticks) together with
the reliable longterm insecticidal, acaricidal and repellent
efficacy in the various European flea and tick species
became evident in the course of the described laboratory
work and has been confirmed now by the excellent
results of the herein described field studies. This long-
term efficacy is useful for full season protection in most
climatic areas, where fleas and ticks exhibit a significant
problem. Overgaauw [25] reports that the main problem
in the control of flea and tick infestation is caused by the
inadequate frequency and duration of treatments given
by owners. According to Overgaauw, 62% of treatment
failures are caused by inadequate treatment frequency
and duration. The imidacloprid 10%/flumethrin 4.5% col-
lar offers unique options for the easy, long-term and sus-
tained control of fleas and ticks and may help overcome
the problems of owner compliance.
Flea allergic dermatitis
The one group of animals that is highly dependent on
strict owner compliance especially for flea control are
those suffering from FAD. Although any modern flea pro-
tective spot on product states on its label that treatment
aids FAD control, FAD patients prescribed these products
frequently suffer from the intermittent in- and decrease of
flea populations due to inadvertently prolonged inter-
treatment intervals caused by poor owner compliance.
The imidacloprid 10%/flumethrin 4.5% collar showed in
the field studies a high potential to cure and prevent FAD:
out of 18 (cat) and 23 (dog) FAD cases found in the cat
and dog population the 5 (cat)/1 (dog) initial glucocorti-
coid treated animals represent 28% (cat) and 4.3% (dog) of
this subgroup whereas the rest of the cases (72% (cat) and
95.7% (dog)) resolved without any additional treatment.
The FAD curative efficacy of the collar is therefore
obvious, as is the protective efficacy: no further glucocorti-
coid treatment was necessary in this highly flea susceptible
subpopulation throughout the study to prevent further
FAD relapses.
M o r e o v e r ,i no n eF A Dp o s i t ive dog which was treated
one month before the start of the study with a glucocorti-
coid, obviously with limited success (FAD present at study
enrolment) the FAD resolved under exclusive treatment
with the imidacloprid 10%/flumethrin 4.5% collar without
any further palliative treatments. The benefit of FAD treat-
ment by the strict and sustainable flea eradication coupled
with longterm continuous flea control over just palliative
measures is evident.
Safety
With the exception of local reactions at the collar site, no
adverse event in either dogs or cats was evaluated as being
product related. Mainly, the reported cases were slight
signs of dermal irritations most probably due to mechani-
cal rubbing as they all had one thing in common: they
were generally transient and healed under the collar when
the collar was left on the animal. These observations
reflect the experiences made in the extensive series of up
to 5 times overdosed longterm laboratory target animal
safety studies in cats and dogs, kittens and puppies which
were conducted as a prerequisite for conducting the field
studies [12]. These studies showed that the formulation is
safe for cats (from 10 weeks of age) and dogs (from 7
weeks of age) even at a 5 fold overdose and with repeated
(every 2 months) applications. Particularly important was
the confirmation of collar safety in the more drug sensitive
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a member of the pyrethroid class. As described in the
introduction, flumethrin as an active ingredient was found
and proved to be as safe in cats as in dogs. Additionally,
the active ingredients are released from the collar matrix
evenly and without peak concentrations [9] so that no ele-
vated acute active ingredient exposure occurs. Having safe
active ingredients in a safe, slow release formulation
makes the collar an ideal application for the drug sensitive
cat species and allows the use of flumethrin, a potent acar-
icide with fast acting, repellent properties, in a species in
which it is not possible to apply any of the current pyre-
throids (e.g. permethrin, deltamethrin). The undeniable
safety of the collar particularly for cats was additionally
underlined by its mechanical features, which were espe-
cially designed to address the particular concerns of cat
owners. Cat owners may be worried about fitting collars
to cats as they perceive an increased potential risk for cats
to be caught or strangulated while roaming and hunting
outside. The specific safety oriented design (safety closure
mechanism plus a predetermined breakpoint as second
fall back safety feature) will release a cat with comparably
minor extra force. This is reflected by the results of the cat
field study in which no such events were recorded.
Canine vector borne diseases (CVBD)
The above described efficacy gets medical importance
when it is seen in the light of the role of ectoparasites as
potent vectors of bacterial, viral and protozoal diseases, as
briefly outlined in the background section. Besides offering
protection against the parasites themselves and the estab-
lishment of large populations (fleas, R. sanguineus ticks),
an uninterrupted longterm efficacy has another important
benefit; by prevention of parasite bites it also can help pre-
venting vector borne disease transmission. This is obvious
in regions with regular and high flea and especially tick
infestation pressure but holds also true for regions with
more occasionally occurring flea and tick infestations in
which animal owners tend to rely on their own abilities in
finding and removing attached ticks by hand quick enough
to prevent pathogens being transmitted. This is a danger-
ous misinterpretation of the physiological facts. On the
one hand, there is a highly underestimated parasite species
which can act as fast and potent transmitters of vector
borne diseases: the fleas. Besides the well known and by
Europe’s pet owners no longer feared plague bacteria, they
carry a number of e.g. Rickettsia or Bartonella species
which are in many cases zoonoses and therefore of
remarkable medical impact. Especially Bartonellosis,
caused by B. henselae and mainly linked to cats as a reser-
voir, can be regarded as one of the major potential emer-
ging infections of man [26].
On the other hand even not all tick borne pathogens are
t r a n s m i t t e da ss l o w l ya se . g .Babesia canis canis with the
sporozoites needing a maturation of at least 48 hours in
the tick’s salivary glands to become infectious [27]. There
are numerous diseases which are transmitted much faster
(e.g. Ehrlichia canis within 4-6 hours after tick attach-
ment) [28] and a small, attached but still unengorged
female tick can be easily overlooked and so successfully
transmit diseases during this early stage.
The danger of acquiring a tick borne disease is even
increased by the fact that not only the easily visible
adult ticks but also tick larvae and nymphs are highly
important for CVBD transmission according to recent
knowledge [29]. These parasites are nearly invisible
because of their very small size and would not be noted
or removed by the animal owner, but they are potent
vectors due to horizontal transmission (larvae are
infected and transfer the pathogen during moulting to
the nymph stage) or even vertical transmission (an
infected adult transfers the pathogen via the eggs to the
next larvae/nymph generation: occurs e.g. in Borrelia,
Babesia) [30]. As the number of the juvenile stages
usually exceeds by far the number of adult ticks, they
form a serious threat for animals exposed to their habi-
tats. The susceptibility of tick stages against imidaclo-
prid/flumethrin declines from larva > nymph > adult
ticks. According to the European guideline EMEA/
CVMP/005/2000, this is expected, but it was further-
more proven in particular during the development of
the imidacloprid 10%/flumethrin 4.5% collar [9].
Conclusion
Seresto
®, an Imidacloprid 10%/Flumethrin 4.5% collar
has been shown to be safe and highly efficacious in the
treatment and prevention of tick and flea infestations in
cats and dogs treated as patients presenting to veterinary
practices under field conditions. The evaluation of effi-
cacy was based on non-inferiority to the control group
treated with a commercial product licensed for this indi-
cation. Efficacy for both tick and flea infestations was
confirmed by at least 90% tick and 95% flea count reduc-
tion in cats and dogs, respectively for the whole study
period. In addition, superiority of the IVP group com-
pared to the control group was confirmed for both flea
and tick count reduction at various time points.
Containing two highly potent yet safe active ingredients,
the neonictinid imidacloprid and the a-cyano-pyrethroid
flumethrin, the imidacloprid 10%/flumethrin 4.5% collar
with its slow release formulation proved to be very safe in
both dogs and cats. Especially for cats, this product pro-
vides the first longterm acaricidal and tick repellent treat-
ment on the market.
The imidacloprid 10%/flumethrin 4.5% collar will
t h e r e b yc o n t r i b u t em a r k e d l yt ot h ee f f e c t i v ea n ds a f e
protection of cats and dogs against ectoparasites and
consequently vector borne diseases.
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